Study Finds Cardiovascular Benefits of GLP-1 Drugs May Fade After Stopping Treatment
A large study has found that the cardiovascular benefits of GLP-1 receptor agonists—including popular weight-loss and diabetes drugs such as Ozempic, Wegovy, Mounjaro, and Zepbound—may disappear relatively quickly after patients stop taking the medications.
Researchers examined outcomes for patients who discontinued these treatments and found that after two